Unlike older weight loss drugs that target a single hormone pathway, retatrutide activates three separate receptors: GLP-1 (glucagon like peptide 1), which slows digestion and reduces appetite GIP (glucose dependent insulinotropic polypeptide), which helps regulate blood sugar and insulin release Glucagon, which increases energy expenditure and supports fat burning By working on all three pathways together, retatrutide aims to produce a stronger combined effect than medicines that only target one or two of these hormones, such as semaglutide or tirzepatide
FADD, Fas Associated Via Death Domain
Wegovy is also now available as a daily pill
We have unimolecular, dual agonist, tri-agonist, [and] tetra-agonists, where you can just add an alkyl group, and then you can tune GLP-1 receptor [sensitivity] up or down, says Kumar
doi: 10.1186/s13059-014-0550-8 58 MaM.JiangW.ZhouR